TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04210570
Drug: Chemical granulate absorber
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemical granulate absorber trap CO2 chemically in granules that are later disposed of when absorption capacity is reached
Study: NCT05223101
Drug: Drug: Micardis 80 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration of telmisartan 80 mg
Study: NCT04516681
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5g/kg/day, D1-3, every 2 weeks
Study: NCT04516681
Drug: FOLFOX Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 130 mg/m² d1 concurrent with Leucovorin 400 mg/m², followed by Oxaliplatin 85 mg/m² d1 followed by Bolus 5FU 400 mg/m² , followed by Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks with or without bevacizumab 5mg/kg, every 2 weeks
Study: NCT00000899
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05615467
Drug: LY3556050
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05578404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo to Vit D
Study: NCT06417281
Drug: 5 Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3±1 hours before anesthesia, participants will take 5-ALA orally at a dosage of 20 mg/kg, followed by fluorescence-guided resection of malignant glioma.
Study: NCT04654689
Drug: G04CB02
Approvals — FDA: no, EMA: no, PMDA: no
Description: G04CB02, in a single daily dose for 4 months
Study: NCT05558410
Drug: HB/APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules for oral administration.
Study: NCT05558410
Drug: Placebo (matched to VX-548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to VX-548 for oral administration.
Study: NCT05558410
Drug: Placebo (matched to HB/APAP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to HB/APAP for oral administration.
Study: NCT04779645
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-Week, once weekly subcutaneous injection with placebo
Study: NCT05920213
Drug: L-ornithine L-aspartate
Normalized name: L-ornithine L-aspartate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30g/24 hours in 3 divided doses for 5 days
Study: NCT05159193
Drug: pegylated liposomal doxorubicin (PLD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegylated liposomal doxorubicin (PLD) 30 mg/m\^2, i.v., d1, q3w
Study: NCT05159193
Drug: cyclophosphamide (C)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide (C) 600 mg/m\^2, i.v., d1, q3w
Study: NCT04558502
Drug: Minocycline hydrochloride capsule
Normalized name: Minocycline Hydrochloride Capsules
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic for H. pylori eradication
Study: NCT04558502
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic for H. pylori eradication
Study: NCT05647993
Drug: Azithromycin Injection [Zithromax]
Normalized name: azithromycin Injection [Zithromax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group patient will receive standard antimicrobial prophylaxis(cefazolin intravenously weight dependent) and azithromycin 500 mg intravenously before the incision
Study: NCT04654507
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05367661
Drug: CHK336
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT05367661
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT05374343
Drug: pyroglutamate rongliflozin capsules
Normalized name: pyroglutamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive one 50mg capsule orally (by mouth) on Day 1
Study: NCT04691661
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03528681
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension administered orally placebo once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.
Study: NCT04689308
Drug: MH048
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Soft gel capsules 5 mg and 25 mg，oral MH048 should be administered after an overnight fast.
Study: NCT04727515
Drug: fentanyl 2µg/kg intravenously and maintained with isoflurane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia will be induced using titration of intravenous propofol till loss of verbal contact and fentanyl 2µg/kg intravenously and maintained with isoflurane (end tidal up to 1.5%), oxygen in air 50:50 via a laryngeal mask.
Study: NCT06598943
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered
Study: NCT06574204
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The researchers injected 30 units of erythromycin into the inner right wrist of the subjects, which is a liquid dosage form.
Study: NCT06574204
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The researchers injected 30 units of azithromycin into the inner right wrist of the subjects, which is a liquid dosage form.
Study: NCT06590870
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The fentanyl solution for administration will be prepared by diluting 2 mL of fentanyl 50 µg/mL with 8 mL of normal saline (bacteriostatic 0.9% sodium chloride) for a fentanyl solution of 10 µg/mL.
Study: NCT06590870
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The normal saline solution for administration will be bacteriostatic 0.9% sodium chloride.
Study: NCT06059885
Drug: Tislelizumab plus tyrosine kinase inhibitor
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib, tyrosine kinase inhibitor (TKIs)
Study: NCT05809687
Drug: DKP21102_B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment
Study: NCT05809687
Drug: DKP21102_A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Control
Study: NCT04711837
Drug: HSK3486
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK3486 for induction of general anesthesia.
Study: NCT05035498
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A maintenance dose of norepinephrine (0.05 μg/kg/min) infusion simultaneous with subarachnoid block
Study: NCT04629729
Drug: FT819
Normalized name: Furmonertinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Interventional Therapy
Study: NCT04629729
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lympho-conditioning agent
Study: NCT03883893
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen will be given in the OR.
Study: NCT00117078
Drug: Aranesp®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05863936
Drug: Methylprednisolone Injectable Suspension
Normalized name: methylprednisolone Injectable Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone pulse therapy, total dose from 1500mg to 3000mg.
Study: NCT05863936
Drug: Immunosuppressive Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Mycophenolate Mofetil, oral, 1.0-1.5g per day;~2. Tacrolimus, oral, 2-4mg per day.
Study: NCT05356793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH-1 vehicle minus active components eyedrop
Study: NCT04377945
Drug: Part 1, JM-010 component Group A
Approvals — FDA: no, EMA: no, PMDA: no
Description: JM-010 component Group A
Study: NCT04377945
Drug: Part 1, JM-010 component Group B
Approvals — FDA: no, EMA: no, PMDA: no
Description: JM-010 component Group B
Study: NCT04377945
Drug: Part 1, JM-010 component Group C
Approvals — FDA: no, EMA: no, PMDA: no
Description: JM-010 component Group C
Study: NCT04377945
Drug: Part 1, Placebo Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Group
Study: NCT04377945
Drug: Part 2, JM-010 combination Group A
Approvals — FDA: no, EMA: no, PMDA: no
Description: JM-010 combination Group A
Study: NCT04377945
Drug: Part 2, JM-010 combination Group B
Approvals — FDA: no, EMA: no, PMDA: no
Description: JM-010 combination Group B
Study: NCT04377945
Drug: Part 2, Placebo Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Group
Study: NCT04150458
Drug: 18F-fluorocholine PET/CT.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F-fluorocholine positron emission tomography / computed tomography
Study: NCT05559814
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraluminal flushing of placebo solution through the scope during scope withdrawal
Study: NCT05902728
Drug: HLX208
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive treatment HLX208 900 mg in the fast state followed by 7 days washout ，then receive treatment HLX208 900 mg in the fed state
Study: NCT05902728
Drug: HLX208
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive treatment HLX208 900 mg in the fed state followed by 7 days washout ，then receive treatment HLX208 900 mg in the fast state.
Study: NCT05902728
Drug: HLX208
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg
Study: NCT05076422
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06001619
Drug: Prostate hyperplasia medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosages prostatic hyperplasia medication: dutasteride 0,5 MG x1 or finasteride 5 MG x1 or combination of dutasteride and tamsulosin 0,5/0,4 MG x1.
Study: NCT06001619
Drug: LhRH-antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose in prostatic cancer patient cohort of LHRH antagonist degarelix is 120 MGx2 and the maintenance dose is 80 MGx1.
Study: NCT06033989
Drug: sandblasted, and acid-etched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed dental implant placement after application of surface treatment to enhance Osseointegration and healing .
Study: NCT05282004
Drug: SOK583A1
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOK583A1 will be provided in a vial kit, with 40 mg/mL of aflibercept solution for IVT injection (2 mg/0.05 mL)
Study: NCT05347069
Drug: No aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aspirin administered
Study: NCT06040177
Drug: Renvatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renvatinib: 8mg (weight \<60kg) or 12mg (weight 60kg) once a day until disease progression, intolerable toxicity
Study: NCT05418049
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill
Study: NCT04898907
Drug: ANG-3777 (Therapeutic Dose)
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arms assigned to this intervention will receive 2 mg/kg, IV, Fasted
Study: NCT06528314
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT06670196
Drug: SKB264
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4mg/kg, intravenous (IV) infusion
Study: NCT06669351
Drug: ZX-7101A
Approvals — FDA: no, EMA: no, PMDA: no
Description: On day1: Take two tablets of ZX-7101A orally once (specification: 10mg/ tablet) with appropriate amount of warm water
Study: NCT05347485
Drug: Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphodepleting therapy (cyclophosphamide and fludarabine) will be administered intravenously.
Study: NCT04898907
Drug: ANG-3777 (Supra-therapeutic Dose)
Normalized name: Supra Sulfa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arms assigned to this intervention will receive 6 mg/kg, IV, Fasted
Study: NCT04898907
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arms assigned to this intervention will receive normal saline, IV, Fasted
Study: NCT01543750
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04919564
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9% 2 cc/hour for a period of 12 hours since anesthetic induction
Study: NCT05629962
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets administered orally every 12 hours (twice a day) for a total of 5 days
Study: NCT05503953
Drug: AGSAVI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uptitation
Study: NCT06676891
Drug: RZ-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single intracerebral injection of RZ-001, Recombinant adenovirus harboring the modified ribozyme construct with HSV-tk as a therapeutic transgene
Study: NCT04734873
Drug: Placebo + SOC
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV placebo plus standard of care
Study: NCT06010810
Drug: 4% Topical Hidroquinone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will be given 4% Topical Hidroquinone, on half of the face, twice a day for 2 months
Study: NCT06334133
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05681728
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion
Study: NCT04685148
Drug: Transdermal patch estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol patches (200 μg per day by transdermal delivery) will be administered at day 0 (+1) to day 21 postpartum.
Study: NCT04685148
Drug: Transdermal patch placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patches will be administered at day 0 (+1) to day 21 postpartum.
Study: NCT05269628
Drug: Placebo CBD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution will be taken twice per day, using the same dosing regimen as described for Epidiolex®.
Study: NCT05269628
Drug: Placebo THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules will be taken twice per day in the same schedule and manner as active dronabinol.
Study: NCT06530706
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same volume of normal saline was pumped slowly after intubation, followed by the same volume of NS until the end of the operation. In the PCIA pump, only sufentanil was used.
Study: NCT06676319
Drug: Short-Acting Beta Agonists (SABA)
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Varies and depends on pharmaceutical presentation-Route of administration:Oral Inhalation
Study: NCT06676319
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Solution for injection in vial-Route of administration:Subcutaneous injection
Study: NCT05063370
Drug: Standard Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will not receive Levosimendan and will receive standard care according to the institution protocol
Study: NCT06611163
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo SC injection at Day 1 and Week 4
Study: NCT06610890
Drug: Hemay005
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 15mg tablet, four tablets at a time
Study: NCT06205030
Drug: anti-diabetic herbal drug
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: All the volunteers directed to the laboratory so that biochemical tests can be performed on them before taking the drug. Volunteers are asked to take the received NOSHIN SHAHD drug 20 ml three times per day after food. at the end of the six week. then, the sample collection will be done to review all the tests of the end stage of receiving the drug.
Study: NCT06503679
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT05398445
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a placebo subcutaneously.
Study: NCT06253871
Drug: IAM1363
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, immediate release capsules of IAM1363
Study: NCT05312645
Drug: Diclofenac 1% Topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 grams topically four times daily for 2 weeks to posterior cervical spine
Study: NCT06488781
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 500 milligrams intravenously once and cefazolin 2 grams intravenously every 8 hours for up to three doses
Study: NCT06488781
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given in place of other two active drugs
Study: NCT05430867
Drug: GV-971 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: GV-971 450mg twice a day
Study: NCT06308653
Drug: Inactive Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The inactive placebo is encapsulated within a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of Microcrystalline Cellulose (MCC). The MCC is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use.
Study: NCT00497120
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05319314
Drug: GCC19CART
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single infusion of Chimeric Antigen Receptor (CAR) transduced autologous T cells administered intravenously (i.v.)
Study: NCT06604325
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All women recruited to Group B will receive 100 ml Normal Saline as intravenous infusion 10 minutes before the skin incision.
Study: NCT06672666
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partcipants will be given placebo substance to be taken with titrated instructions that mimic IP dispensing method daily for 4 weeks
Study: NCT06588348
Drug: Steroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: All enrolled subjects will be prescribed a 14-day course of corticosteroid therapy in the form of Prednisone 20 mg to be taken once daily by mouth.
Study: NCT06602258
Drug: E2814
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E2814 IV infusion.
Study: NCT06602258
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV infusion.
Study: NCT06679153
Drug: VVN461 Ophthalmic Solution 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: VVN461 Ophthalmic Solution, 1.0%, for up to 28 days
Study: NCT06679153
Drug: VVN461 Ophthalmic Solution 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: VVN461 Ophthalmic Solution, 0.5%, for up to 28 days
Study: NCT06679153
Drug: Prednisolone acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone acetate, 1%, for up to 28 days
Study: NCT06453694
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of placebo will be administered by a healthcare provider on Day 0 and Day 3 of the trial.~Rescue therapy with therapeutic plasma exchange will be given to any participant based on the results of Day 7 evaluation.
Study: NCT06187506
Drug: Bacillus Calmette Guerin Vaccine
Normalized name: BACILLUS CALMETTE-GUERIN,TICE VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy, i.e., intravesical therapy once a week for 6 weeks. maintenance therapy, i.e., one course of maintenance therapy at three, six and twelve months after surgery, each course once a week for 3 weeks.
Study: NCT05619926
Drug: STSP-0601 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Injection
Study: NCT04349930
Drug: Placebo vaginal suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vaginal suppository
Study: NCT05476796
Drug: Trifluridine/Tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluridine/Tipiracil will be administered with a 14-day schedule (35 mg/m² BID for 5 days followed by 9 days of recovery) until disease progression or intolerable toxicity.
Study: NCT05476796
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folinic Acid 400 mg/m² (or 200 mg/m² if L-folinic acid) + oxaliplatin 85 mg/m² (infusion duration: 2 hours) followed by 5-FU bolus 400 mg/m² and then 5-FU 2400 mg/m² as a 46-hour continuous infusion. Treatment repeated every 14 days. In case of limiting-oxaliplatin neuropathy and in all cases after 8 cycles, oxaliplatin will be stopped and 5-FU (simplified LV5FU2 regimen) or capecitabine (1000 mg/m² BID during 2 weeks every 3 weeks) will be continued alone until disease progression or intolerable toxicity.
Study: NCT05564858
Drug: FDA022 Monoclonal antibody-drug conjugate for injection Phase Ib
Normalized name: MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDA022-BB05, intravenously infusion, q3w
Study: NCT04837885
Drug: LUTATHERA® by intra-arterial hepatic (IAH) injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: One treatment dose of LUTATHERA® by IAH injection for the 10 first patients with an PET/CT ratio greater then 3.~The LUTATHERA® by intra-arterial hepatic injection treatment is realised after the conventional treatment by 4 intravenous administrations
Study: NCT05749588
Drug: A1: SHR-A1811
Approvals — FDA: no, EMA: no, PMDA: no
Description: A1: an anti-HER2 antibody-drug conjugate (ADC)
Study: NCT05749588
Drug: C2: SHR-A1811 with BP102
Approvals — FDA: no, EMA: no, PMDA: no
Description: C2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC)~BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)
Study: NCT05749588
Drug: D1: TROP2 ADC
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
Study: NCT05749588
Drug: E1: SHR-A1811
Approvals — FDA: no, EMA: no, PMDA: no
Description: E1: an anti-HER2 antibody-drug conjugate (ADC)
Study: NCT05749588
Drug: F1: TROP2 ADC
Approvals — FDA: no, EMA: no, PMDA: no
Description: F1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
Study: NCT04207710
Drug: Gebauer's Pain Ease Top Aerosol Mist Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical refrigerant spray